Most physiological processes in mammals are influenced by circadian rhythms. These rhythms are driven by a master clock within the hypothalamic suprachiasmatic nuclei (SCN) that synchronizes numerous subsidiary oscillators in peripheral tissues. The circadian clockwork in both the SCN and the peripheral cells is composed of transcription-translation feedback loops maintained by a core set of clock genes (Shearman et al., 2000; Reppert and Weaver, 2002; Schibler and Sassone-Corsi, 2002; Ishida, 2007) . Two transcription factors, Clock and Bmal1, activate their targets, Period (Per1, 2 and 3) and cryptochrome (Cry1 and Cry2); subsequently, the Per and Cry proteins interfere with Bmal1:Clock activity thereby forming the major negative circadian feedback loop. The central clock, through neural, hormonal and metabolic signals, synchronizes the peripheral oscillators, which in turn drive the expression of downstream clock-controlled genes in a tissue-specific manner (Panda et al., 2002; Storch et al., 2002; Miller et al., 2007) . Consequently in various tissues, circadian rhythms impinge upon many physiological processes and pathological conditions, including cancer (Fu et al., 2002; Matsuo et al., 2003; Lowrey and Takahashi, 2004; Ko and Takahashi, 2006) . Recent studies suggested that circadian disruption is associated with breast tumorigenesis (Hansen, 2001; Chen et al., 2005) . The steroid hormone estrogen is essential for normal mammary gland physiology, and is also a potent mammary mitogen (Sternlicht, 2006; Yager and Davidson, 2006) . Although the circadian clock has been linked to several steroid hormone activities, the molecular mechanisms underlying the function of core clock genes in mammary tissue are largely unknown. We hypothesized that circadian regulation may be implicated in hormone homeostasis and hormone-related tumorigenesis in breast epithelia cells.
Estrogen stimulation is thought to be a major factor contributing to the development of breast cancer. Deregulation of the core clock factor, Per2, has been reported in several human malignancies including breast cancer (Chen et al., 2005) . We hypothesized that Per2 function in mammary epithelia cells could be linked to the ERa signaling pathway. ERa regulates transcription of target genes through an interaction with consensus estrogen response elements (EREs). We performed reporter assays with an ERE-luciferase reporter gene to test the effect of Per2 on ERa transactivation ( Figure 1a) . The ERa-positive breast cancer cell line, MCF-7, was cotransfected with ERE-luciferase and either Per2 or empty vector. While 17-b estradiol (E2) induced high luciferase activity in the control cells, Per2 expression substantially reduced this activity. Per2 also inhibited E2-activated ERE transcription in two additional ERa-positive cancer cell lines, T47D (breast) and Ishikawa (endometrial). In contrast, silencing of Per2 by small interfering RNA (siRNA) (as shown in Figure 1d ) in those cells enhanced the ERE reporter activity (Figure 1a) . We also examined whether Per2 can endogenously suppress ERa-responsive genes ( Figures  1b and c) . MCF-7 cells transfected with either Per2 or a control vector were treated with E2; and the mRNA levels of the known ERa targets, pS2, cyclin D1 and CCN1 were measured by real-time PCR (Figure 1b) . While expression of Per2 alone had little effect on expression of those genes, it strongly inhibited E2-mediated induction of pS2, and further reduced the levels of cyclin D1 and CCN1 below basal level. Moreover, Per2 siRNA enhanced E2-activation of the ERa target genes ( Figure 1b) . Western blot analysis showed a parallel effect of Per2 on the protein levels of cyclin D1 and CCN1 (Figure 1c ). These results suggest that Per2 could be involved in breast cancer prevention by inhibiting E2-induced proliferation. Recently, Per2 was also suggested to play a role in normal mammary cell differentiation (Metz et al., 2006) .
In the absence of ligand, ERa is sequestered in the cytoplasm in an inhibitory protein complex. Upon binding to E2, ERa undergoes conformational changes facilitating cofactor binding and nuclear localization (McDonnell and Norris, 2002) . Immunoprecipitation experiments showed that Per2 associates with ERa in 293T and MCF-7 cells, and E2 stimulation enhances the interaction (Figure 2a) . Moreover, glutathione S-transferase (GST) pull-down assays, with an in vitrotranslated Per2 and a GST-ERa fusion protein, demonstrated direct binding of these proteins ( Figure 2b ). As Per2 shuttles between the nucleus and the cytoplasm (Yagita et al., 2002) , it could change the subcellular distribution of ERa. To test this possibility, 293T cells cotransfected with ERa and V5-tagged mPer2, and MCF-7 cells transfected with V5-tagged mPer2 were treated with E2 and analysed by confocal microscopy. Strong nuclear staining of ERa was detected in the 293T cells ( Figure 2c ). Also, ERa localized mainly to the nucleus in both nonexpressing and Per2-expressing MCF-7 cells. These results indicate that Per2 does not prevent nuclear localization of ERa. Colocalization of Per2 and ERa was noted in both cell lines. Notably, Per2-expressing MCF-7 cells exhibited changes in morphology indicative of apoptosis, such as cell rounding and detachment, while the 293T cells had normal morphology.
ERa is a short-lived protein and binding of E2 further accelerates its degradation (Reid et al., 2002) . While Per2 expression had no effect on ERa mRNA levels (Figure 2d ), it markedly downregulated ERa protein levels in MCF-7 cells (Figure 2e ). PS-341, a specific proteasome inhibitor, blocked Per2-stimulated downregulation of ERa (Figure 2f) showing that Per2-mediated ERa degradation is through the proteasome pathway. Moreover, suppression of endogenously expressed Per2 by siRNA led to stabilization of ERa (Figure 2g ), suggesting that Per2 is necessary for efficient proteasome-induced degradation of ERa. A recent study showed that several nuclear receptors are clock-controlled genes . Although ERa does not exhibit a circadian expression pattern in normal cells, it is downregulated in Clock mutant mice (Miller et al., 2007) , suggesting that core circadian components have an important role in regulating ERa expression. Protein degradation plays a role in the circadian transcription-translation feedback loops, and core clock factors modulate protein stability through the proteasome pathway in other systems as well (Yagita et al., 2002; Gallego and Virshup, 2007) . Together, these Per2 links the circadian system to ER S Gery et al studies suggest that control of protein turnover is an important feature of circadian regulation. Recent studies in rats showed Per2 is differentially regulated by E2 in specific tissues (Nakamura et al., 2005; Perrin et al., 2006) . We found that Per2 mRNA levels were induced by E2 in ERa-positive breast cancer cell lines (Figure 3a) , showing that the human Per2 gene is E2-inducible in mammary epithelial cells. Analysing the Per2 promoter, we identified a potential ERE binding site at À365 bp. The ERE and the surrounding nucleotides are conserved between mouse and human Per2 promoters, suggesting functional significance (Figure 3b) . Electrophoretic mobility shift analyses demonstrated protein-DNA binding between the ERE element from the Per2 promoter and E2-treated MCF-7 nuclear extracts (Figure 3c ). The protein binding was specific as it could be competed with excess cold probe; and the addition of ERa antibody resulted in a supershift of the protein-DNA complex. No specific complexes were detected using nuclear extracts from control cells, nor in parallel experiments with a mutated probe. Furthermore, chromatin immunoprecipitation assays with MCF-7 cells detected the presence of ERa on the upstream regulatory region of Per2 following E2 treatment (Figure 3d ), demonstrating that endogenous ERa binds to the Per2 promoter. Several additional half-ERE sites were found within the Per2 promoter, which may also contribute to the E2-induction of Per2. Hormone-mediated gene expression is attenuated rapidly; inducible expression of corepressors might serve as a mechanism to control the magnitude of ERa transcriptional activation. Indeed, other ERa corepressors including BRCA1 and SHARP are also E2 inducible (Romagnolo et al., 1998; Shi et al., 2001) . In this regard, regulation of circadian genes by E2 may help maintain hormonal homeostasis.
Per2 mutant mice show increased susceptibility to tumor development, suggesting that Per2 is a tumor suppressor gene (Fu et al., 2002) . Expression of Per2 dramatically reduced the growth of MCF-7 cells on plastic and the ability of the cells to form colonies on soft agar (Figures 4a and b) . Per2-induced growth inhibition was associated with a significant increase in apoptotic death, measured by Annexin-V staining and Per2 links the circadian system to ER S Gery et al poly-(ADP-ribose)polymerase cleavage (Figures 4c and  d) . A recent study also found that Per2 induced apoptosis in murine lung and breast cancer cell lines (Hua et al., 2006) . These results show that Per2 has antiproliferative effects in breast cancer cells and suggest that dysregulation of this gene could play a role in mammary tumorigenesis. The circadian transcriptional network allows the orchestration of physiology and behavior for optimal adaptation of the organism to its environment. We identified Per2 as a novel estrogen-inducible ERa corepressor, suggesting a feedback mechanism coupling the circadian clock to the estrogen pathway. Our results further support a model wherein, while circadian regulation helps maintain estrogen homeostasis in normal mammary cells, disruption of this regulation could play a role in the development of hormone-related breast cancer (Figure 4e ). Further, elucidating the connections between clock genes and the ER network could benefit the development of new therapeutic strategies for breast cancers, as well as, provide insights into chronotherapy, as a way to optimize current therapies. 
